Moderna (MRNA) Stock: Biotech Leader Surges 30% on Updated Guidance

TLDR Moderna shares climbed 30% during the first eight trading days of 2026, leading all S&P 500 stocks Revenue guidance increased to roughly $1.9 billion for 2025 with planned reductions in operating costs Technical indicators show a golden cross formation and breakout above the $36 resistance level Analysts forecast 10% annual revenue growth from vaccine [...]

The post Moderna (MRNA) Stock: Biotech Leader Surges 30% on Updated Guidance appeared first on Blockonomi.